Evidence map›Paper›PMID 27686519›Full record

ReviewHeart (British Cardiac Society)2016

Influenza vaccine as a coronary intervention for prevention of myocardial infarction.

C Raina MacIntyre, Abela Mahimbo, Aye M Moa, Michelle Barnes

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart (British Cardiac Society), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. The impact of COVID-19 and COVID vaccination on cardiovascular outcomes.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  18. What if flu vaccination is the most responsible thing to do for cardiovascular health in the upcoming season?European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

C Raina MacIntyreSchool of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.
Abela MahimboSchool of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.
Aye M MoaSchool of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.
Michelle BarnesSchool of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.
UNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Influenza is one of the leading infectious causes of morbidity and mortality globally, and evidence is accumulating that it can precipitate acute myocardial infarction (AMI). This is thought to be due to a range of factors including inflammatory release of cytokines, disruption of atherosclerotic plaques and thrombogenesis, which may acutely occlude a coronary artery. There is a large body of observational and clinical trial evidence that shows that influenza vaccine protects against AMI. Estimates of the efficacy of influenza vaccine in preventing AMI range from 15% to 45%. This is a similar range of efficacy compared with the accepted routine coronary prevention measures such as smoking cessation (32-43%), statins (19-30%) and antihypertensive therapy (17-25%). Influenza vaccine should be considered as an integral part of CVD management and prevention. While it is recommended in many guidelines for patients with CVD, rates of vaccination in risk groups aged <65 years are very low, in the range of 30%. The incorporation of vaccination into routine CVD prevention in patient care requires a clinical practice paradigm change.

Indexed as

AnimalsAntihypertensive AgentsDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionInfluenza, HumanInfluenza VaccinesMyocardial InfarctionRisk AssessmentRisk FactorsSecondary PreventionSmokingSmoking CessationSmoking PreventionTreatment OutcomeAntihypertensive AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsInfluenza Vaccines

Identifiers

PMID27686519
PMCPMC5256393
OpenAlexW2525383895

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.